Table 1.
Patient # | Side | Age/Sex | % WR | BC‐PTA | Stapedectomy | Treatment Post Stapedectomy | Treatment |
---|---|---|---|---|---|---|---|
1 | AD | 56 M | 98 | 30 | Yes | Yes | Risedronate (x4wk), |
AS | 46 | 46.25 | Yes | Yes | Zoledronate | ||
2 | AD | 55 F | 54 | 68.75 | Yes (x2) | Yes | Zoledronate (x3) |
AS | 72 | 60 | No | ‐ | |||
3 | AD | 54 F | 76 | 65 | Yes | Yes | Zoledronate |
AS | 90 | 73.75 | Yes | No | |||
4 | AD | 36 M | 76 | 51.25 | Yes | Yes | Risedronate |
AS | 90 | 36.25 | No | ‐ | |||
5a | AD | 31 F | 96 | 43.75 | No | ‐ | Risedronate |
AS | 98 | 46.25 | No | ‐ | |||
6 | AD | 54 M | 38 | 68.75 | Yes | Yes | Zoledronate |
AS | 28 | 66.25 | No | ‐ | |||
7 | AD | 52 M | 94 | 41.25 | Yes (x2) | Yes | Zoledronate |
AS | 82 | 36.25 | Yes | Yes |
AD exploratory tympanotomy revealed mobile ossicles with obliterated round window
Wk = weeks, listed audiometric data are bisphosphonate pretreatment values